Area of investment and support

Area of investment and support: Myalgic encephalomyelitis / chronic fatigue syndrome, also known as ME/CFS

The aim of this programme is to support high quality and collaborative research into myalgic encephalomyelitis / chronic fatigue syndrome, also known as ME/CFS, a complex and serious debilitating medical condition with a diverse range of symptoms.

Duration:: Ongoing
Partners involved:: Medical Research Council (MRC)

Show related funding opportunities

The scope and what we're doing

Supporting and enabling a strong portfolio of ME/CFS research has been a high priority for MRC for several years.

ME/CFS is a complex and serious debilitating medical condition with a diverse range of symptoms. The most well known of these is profound physical or mental fatigue (or both), while others include pain, disturbed sleep patterns and gastrointestinal problems. Each patient experiences their own personal combination of symptoms.

Why we're doing it

There is an unmet clinical need for better diagnosis and treatments for people living with ME/CFS.

Opportunities, support and resources available

Funding opportunities

Researching ME/CFS: priority area

Closing date: Open - no closing date

MRC has supported this area of research through a cross-board highlight notice since 2003.

High quality applications are invited to any of MRC’s research boards or fellowship schemes, as appropriate, based on the scientific or clinical area.

Find out how MRC decides which research proposals to fund.

Strategic initiatives

In addition to response-mode funding, MRC continues to support ME/CFS research through the DecodeME strategic initiative.

DecodeME

In 2020, MRC and the National Institute for Health Research (NIHR) jointly funded the £3.2 million DecodeME study (£1.4 million from NIHR and 1.8 million from MRC).

The study analysed samples from 20,000 people with ME/CFS to search for genetic differences that may indicate underlying causes or increase the risk of developing the condition. The research is the world’s largest genome-wide association study of ME/CFS and hopes to aid the development of diagnostic tests and targeted treatments.

The study is led by a collaboration of researchers, people with ME/CFS, carers and advocates and is due to end in early 2026.

NIHR and MRC post-infection conditions research showcase

As part of our work to facilitate research in this important area MRC, in partnership with the NIHR, hosted a post-infection conditions research showcase in November 2025. The research showcase brought together researchers, funders and patient representatives to discuss findings from the DecodeME project and other investments, including input from a senior representative at Precision Life.

See a summary of the showcase.

MRC continues to work in partnership with NIHR to support queries and potential future grant applications arising from this event.

ME/CFS Priority Setting Partnership

In 2022, MRC co-funded an ME/CFS Priority Setting Partnership to identify the top 10+ ME/CFS research priorities. The partnership was led by people with ME/CFS, their carers and clinicians, and facilitated by non-profit making initiative, the James Lind Alliance.

We would particularly welcome proposals that address 1 or more of the research areas identified by the ME/CFS Priority Setting Partnership under the MRC ‘researching ME/CFS: highlight notice’.